Abstract | OBJECTIVE: This study examines the target specificity of tetrathiomolybdate (ATM), an anti-angiogenic, anti- tumor agent against the viability / proliferation of arterial, venous, capillary endothelial and tumor cells. MATERIALS AND METHODS: Cells were seeded at 10 or 100% density (to measure viability / proliferation respectively) in medium +/- 0-250 uM ATM. Viability and proliferation were measured by metabolic labeling-colorimetry. One-way ANOVA + Bonferroni testing examined base metabolism; Dunnett's testing was used for viability/proliferation. RESULTS: Venous proliferation showed high ATM sensitivity (50% reduction ~ > or =5 uM ATM, p<0.01), capillary proliferation was inhibited > or =10 uM (p<0.05). Arterial endothelium were less sensitive to ATM, (50% inhibition ~ > or = 20 uM, p<0.01). YPEN-1 were inhibited >50 uM ATM. Capillary viability was inhibited > or =20 microM ATM (p<0.01); venous, arterial and tumor viability show less ATM sensitivity. CONCLUSIONS: Our data suggest that venous and capillary endothelial proliferation are important targets in ATM therapy, but that other vascular segments and tumor cells may be less influenced.
|
Authors | A Carpenter, A Rassam, M H Jennings, S Robinson-Jackson, J S Alexander, C Erkuran-Yilmaz |
Journal | Inflammation research : official journal of the European Histamine Research Society ... [et al.]
(Inflamm Res)
Vol. 56
Issue 12
Pg. 515-9
(Dec 2007)
ISSN: 1023-3830 [Print] Switzerland |
PMID | 18210236
(Publication Type: Journal Article)
|
Chemical References |
- Angiogenesis Inhibitors
- Molybdenum
- tetrathiomolybdate
|
Topics |
- Angiogenesis Inhibitors
(pharmacology)
- Animals
- Cell Line, Tumor
- Cell Proliferation
(drug effects)
- Cell Survival
(drug effects)
- Endothelial Cells
(cytology, drug effects)
- Endothelium, Vascular
(cytology)
- Humans
- Molybdenum
(pharmacology)
- Rats
|